Midatech Pharma Inc. (NASDAQ: MTP) stock surged by 2% at last close while the MTP stock price gains by 71.08% in the pre-market trading session. Midatech Pharma is a medication delivery technology business that aims to improve medicine’s bio-delivery and bio-distribution.
What is happening?
MTP announces groundbreaking in vitro results demonstrating Q-ability Sphera’s to synthesize proteins into long-acting injectable medicines, as well as substantial progress on a number of other projects.
Read More
MTP has closed down its Bilbao operations, halving its monthly cash burn rate, and pivoted from a majorly singular focus on one Phase III ready asset to ‘multiple shots on goal’ with a broadened pipeline of nine earlier stage initiatives in the 13 months since the declaration of a Strategic Review. MTP’s goal is to get each program to proof of concept level before looking for licensing partners to help with subsequent stages of research, production, and commercialization.
MTP’s Q-Sphera technology encapsulates medicines in polymer-based bioresorbable microspheres that may be administered into the body to build depots that release the medication over a predicted, sustained period ranging from one week to many months.
One such technique is:
Since biologic products like mAbs and other high molecular weight proteins are fragile and readily denatured in manufacturing, there are no authorized long-acting injectable formulations. MTP has been working on an exemplary mAb and has proven in vitro encapsulation of the mAb as well as functional integrity and antigen-binding.
However,
These findings, according to MTP, have the ability to open up a lot of doors for its Q-Sphera technology. Protein-based medications make up a large portion of today’s medicines, and their reformulation into long-acting injectables might bring considerable benefits to patients, clinicians, and payers. In 2020, the top ten mAbs had worldwide sales of $74.9 billion1 and all mAbs had worldwide sales of $154 billion.
MTP’s next steps will be to improve the medication loading and dissolution profiles of encapsulated mAbs. In the meanwhile, MTP is reviewing a number of high-value mAb therapies for possible inclusion in its own pipeline, as well as replicating the results found in this exemplar mAb.
